BEHCET’S SYNDROME MARKET ANALYSIS

Market Challenges And Opportunities

Global Behcet’s Syndrome Market – Dynamics

Rising management therapies to reduce the worsening of the behcet’s syndrome is anticipated to boost the market growth in the forecast period. For instance, in July 2021, according to Dove Medical Press, the syndrome has a heterogeneous nature, its treatment and management differentiates as per the type of involvement. Joint involvement and mucocutaneous in behcet’s syndrome patients do not result in a permanent damage with proper manifestation. In the behcet’s syndrome, conventional therapy is the primary option. Immunosuppressive therapy, on the other hand, is required in individuals with significant organ involvement. Conventional treatment for management of behcet’s syndrome includes colchicine, azathioprine, cyclosporine-A, and cyclophosphamide to decrease the seriousness of disease is projected to drive the market growth during the forecast period.

Increasing clinical trial studies for evaluating the safety and efficacy of the drugs is estimated to drive the global behcet’s syndrome market growth during the forecast period. For instance, in May 2020, as per the U.S. National Liabraby of Medicine, a study is conducted to evaluate the efficacy and safety of Amgen’s apremilast (CC-10004) in the treatment of behcet’s syndrome. In the treatment of ulcers in the mouth with behcet's syndrome, apremilast is used. Apremilast is approved for adults with oral ulcers associated with behcet’s syndrome, which is anticipated to drive the market growth during the forecast period.